



Inflammation is a target of medical treatment for lower urinary tract symptoms associated with benign prostatic hyperplasia

Cosimo De Nunzio¹ · Andrea Salonia^{2,3} · Mauro Gacci⁴ · Vincenzo Ficarra⁵

Received: 10 December 2019 / Accepted: 23 January 2020 / Published online: 14 February 2020
© The Author(s) 2020, corrected publication 2020

Abstract

Purpose To review the role of a persistent prostatic inflammatory status (PIS) in the development and progression of benign prostatic hyperplasia (BPH) associated with lower urinary tract symptoms (LUTS) and which medical therapies approved for LUTS/BPH may reduce persistent PIS.

Methods Literature search in PubMed up to July 2019.

Results The cause of histologically defined persistent PIS or chronic prostatic inflammation is multifactorial. It is evident in many men with LUTS/BPH, particularly in older men and in men with a large prostate volume or more severe (storage) LUTS. Additionally, persistent PIS is associated with an increased risk of acute urinary retention and symptom worsening. Of medical therapies approved for LUTS/BPH, the current evidence for a reduction of persistent PIS is greatest for the hexanic extract of *Serenoa repens* (HESr). This treatment relieves LUTS to the same extent as α_1 -adrenoceptor antagonists and short-term 5 α -reductase inhibitors. Limited evidence is available on the effect of other mainstream LUTS/BPH treatments on persistent PIS.

Conclusions Persistent PIS plays a central role in both the development and progression of LUTS/BPH. In men with LUTS/BPH who have a high chance of harbouring persistent PIS, HESr will not only improve LUTS, but also reduce (underlying) inflammation. Well-designed clinical studies, with a good level of evidence, are required to better evaluate the impact of BPH/LUTS medical therapies on persistent PIS.

Keywords Prostatic hyperplasia · Prostatic inflammation · Progression · Medical therapy · Phytotherapy · *Serenoa repens*

Electronic supplementary material The online version of this article (<https://doi.org/10.1007/s00345-020-03106-1>) contains supplementary material, which is available to authorized users.

✉ Vincenzo Ficarra
vficarra@unime.it

¹ Department of Urology, Sant'Andrea Hospital, Sapienza University of Rome, Rome, Italy

² University Vita-Salute San Raffaele, Milan, Italy

³ Division of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy

⁴ Minimally Invasive and Robotic Surgery, and Kidney Transplantation, University of Florence AOUC-Careggi Hospital, Florence, Italy

⁵ Department of Human and Pediatric Pathology “Gaetano Barresi”, Urologic Section, University of Messina, Piazza Pugliatti, 1, 98122 Messina, ME, Italy

Introduction

Benign prostatic hyperplasia (BPH) is the most common, chronic, slowly progressing urological disease in elderly men, evident in 50% of men in their 50 s and in 90% in their 80 s [1]. Clinically, it can be associated with benign prostatic enlargement (BPE) and eventually benign prostatic obstruction (BPO), causing bladder outlet obstruction (BOO) along with lower urinary tract symptoms (LUTS) [2]. Among LUTS, it is possible to define symptoms related to the storage and/or the voiding phase of micturition. LUTS have a significant effect on patients' quality of life.

The pathogenesis and progression of BPH is still not fully understood but is most likely multifactorial with increased sympathetic nervous activity, hormonal alterations, the presence of the metabolic syndrome (MetS) [3] and tissue remodelling related to ageing playing a role. In the last decades, growing interest exists for the hypothesis that BPH is an immune-mediated inflammatory disease with

a persistent prostatic inflammatory status (PIS) as a key factor throughout the development and progression of BPH [2]. This review provides the latest update on how persistent PIS and BPH/LUTS are interrelated and the potential impact of LUTS/BPH medical treatment on persistent PIS.

Methods

A non-systematic review of the literature for English-language original and review articles (e)-published up to July 2019 (no date restriction) was performed using the National library of Medicine's PubMed database. The used search strategy included the following terms and limits:

- (Prostatic hyperplasia (Mesh)) AND (Prostatitis (Mesh) OR inflammation), limited for English language, Abstract available, Humans and Title
- "(prostate OR prostatic) inflammation" AND (serenoa OR alfuzosin OR doxazosin OR naftopidil OR silodosin OR tamsulosin OR terazosin OR dutasteride OR finasteride OR tadalafil)
- "serenoa repens" AND ("benign prostatic hyperplasia" OR "BPH")
- "serenoa repens" AND ("benign prostatic hyperplasia" OR "BPH") AND (alfuzosin OR doxazosin OR naftopidil OR silodosin OR tamsulosin OR terazosin OR dutasteride OR finasteride OR tadalafil)


The abstracts of the retrieved records (maximum $N=707$ due to overlap between the papers retrieved from the different searches, Online Resource 1) were screened by three of the authors to identify and read the most relevant articles. Additionally, other significant studies cited in the reference lists of the selected papers were evaluated. Studies published only as abstracts and meeting reports were not included in

the review. Being a non-systematic review, the selection of references was by definition not all-inclusive and selection bias may have occurred.

Persistent prostatic inflammation: definition and etiopathogenesis

An inflammatory reaction in prostatic tissue can be triggered by several factors, including bacterial infections, viruses (e.g., human papilloma virus, herpes simplex virus type 2, and cytomegalovirus), sexually transmitted organisms (e.g., gonorrhoeae and chlamydia), hormones, the MetS, dietary factors, urinary reflux as well as an autoimmune response (Fig. 1) [4–8]. The infiltrating inflammatory cells (70–80% T-lymphocytes, 10–15% B-lymphocytes and 15% macrophages) become activated and release pro-inflammatory cytokines, which in turn increase the expression of several growth factors (e.g., interleukin (IL)-17, IL-15, IL-8, interferon- γ , fibroblast growth factor [FGF] and FGF-2), resulting in abnormal proliferation of the epithelial and stromal cells. The subsequent increased oxygen demand of these cells leads to local hypoxia producing low levels of reactive oxygen species (ROS) promoting angiogenesis and the production of additional growth factors (i.e., vascular endothelial growth factor, IL-8, FGF-2, FGF-7 and transforming growth factor β) [4]. As such, persistent PIS or chronic prostatic inflammation is a histological observation and, irrespective of the mechanism that triggers the uncontrolled inflammatory response, the final result of this process induces tissue damage with subsequent abnormal wound healing and stromal and epithelial cell proliferation and thus BPH [4]. In basic science literature, inflammation is usually described in terms of cellular effectors and released mediators. Several authors have used the score proposed by Irani et al. [9] to classify PIS. This score classifies prostatic inflammation based on the histological grading for the

Fig. 1 Hypothesis on how persistent PIS can develop and how this may contribute to the development and progression of BPH (modified from [5])



extension of inflammatory cells (from grade 0, no inflammatory cells, to grade 3, large inflammatory areas) and for the effect of these cells on prostatic tissue (i.e., aggressiveness grading ranging from grade 0, no contact between inflammatory cells and glandular epithelium, to grade 3, > 25% glandular disruption). The infiltration of inflammatory cells in the prostate during the development of BPH should be differentiated from classical chronic prostatitis, which is related to chronic pelvic pain.

Persistent prostatic inflammation and BPH development/progression

Inflammatory infiltrates have been demonstrated in biopsy samples and surgical specimens of prostatic tissue of patients with LUTS/BPH [4–6]. In 3942 surgery-derived BPH specimens, inflammation was observed in 43%, of which 69% concerned chronic inflammation [10]. The inflammation was significantly associated with age and prostate volume (PV): 61% of prostates 80–89 mL had chronic inflammation versus 8.5% of those 30–39 mL. In 1198 patients with LUTS/BPH from the Medical Therapy of Prostate Symptoms (MTOPS) study, approximately 40% of the baseline prostate biopsy specimens showed chronic inflammatory infiltrates (especially in older men and men with a larger PV) [11]. In 8224 LUTS/BPH patients from the Reduction by Dutasteride of prostate Cancer Events (REDUCE) study, 77.6% of the prostate biopsy samples contained chronic inflammatory cells/persistent PIS. A weak but statistically significant correlation between persistent PIS and an increased PV and the International Prostate Symptom Score (IPSS), particularly the storage subscore, was observed [12]. An autopsy study of 320 prostate glands from men aged 30–80 years showed persistent PIS in 74.5% of the specimens [13]. Men with inflammation were 6.8 times more likely to have BPH than men without inflammation. Furthermore, a study in 282 LUTS/BPH patients undergoing surgery showed persistent PIS in 79%, 48%, and 20% of patients with severe, intermediate, and no LUTS/BPH, respectively [14, 15]. Mean PV was statistically significantly higher in those with high-grade versus those with low-grade inflammation (77 versus 62 mL). The same applied for the mean total IPSS (21 versus 12 points). Other studies have also confirmed that persistent PIS is associated with PV and (storage) symptom severity in men with LUTS/BPH [16].

The impact of persistent prostatic inflammation on BPH progression has also been investigated. In the placebo group of the MTOPS study, LUTS/BPH patients with persistent PIS were at increased risk of developing acute urinary retention (AUR), symptom worsening and the need for BPH-related surgery as compared to those without inflammation [11]. The risk of AUR was 5.6% versus 0% ($P=0.003$), respectively. Also LUTS/BPH patients in the placebo group

of the REDUCE study ($N=4109$) who had persistent PIS at baseline were at increased risk of developing AUR (hazard ratio 1.6–1.8, $P=0.001$) [17]. However, persistent PIS was not associated with symptom worsening over time (median follow-up 41.4 months). Only in patients with a moderate-marked persistent PIS at baseline, a weak association with LUTS/BPH progression was found in post-hoc analyses [17]. The difference between the results from the MTOPS and REDUCE study in terms of symptom progression may have been due to the fact that the REDUCE study included older men and excluded patients with severe BPH (PV > 80 mL and total IPSS > 25 or > 20 while on α_1 -adrenoceptor antagonist treatment) at baseline. Several older, smaller scale studies have confirmed that persistent PIS is not only associated with the development but also with the (faster) progression of BPH [18–20].

Persistent prostatic inflammation and LUTS/BPH: implication for diagnosis and treatment

Until now, histological examination of prostate biopsies remains the only available method to show the presence of inflammatory prostatic cells. As this is feasible only in patients with suspicious prostate cancer, less invasive tools are needed for identifying patients who are at high risk of harbouring persistent PIS. As discussed, patients with severe LUTS (a high total IPSS, e.g., ≥ 20 points), particularly those with storage symptoms, are at increased risk of having persistent PIS [7].

Also those with prostatitis-like symptoms, such as pain and burning sensation, dribbling and hesitant urination, urgency, pain or discomfort of the penis and testicles and painful ejaculations, may have inflammation upon biopsy as shown in another sub-analysis of the REDUCE study [7, 21].

Prostatic calcifications identified at ultrasonography may also provide a hint for the presence of persistent PIS in men with LUTS/BPH. Prostatic calcifications can produce obstruction of the intraprostatic ducts. This stimulates an inflammatory response, characterised by lymphocyte and cytokine activation and ROS release, with subsequent tissue damage and wound healing with stromal proliferation and excessive extracellular matrix production [7, 22].

Additionally, serum/plasma or urine biomarkers could be used to identify LUTS/BPH patients who have a high chance of having persistent PIS [23]. Seminal plasma IL-8 levels [7] are the most reliable and predictive surrogate marker for diagnosing persistent PIS [24, 25] and have been shown to be significantly higher in patients with both LUTS/BPH and chronic prostatitis than in patients with LUTS/BPH only [26]. Unfortunately, the use of this biomarker is expensive and not popular and will therefore probably require further clinical evaluation before it can be introduced in routine clinical practice [22]. Other potential biomarkers [7, 8], still

under investigation, include serum C-reactive protein (CRP), monocyte chemoattractant protein-1 (MCP-1) in prostatic secretions and chemokine (C–C motif) receptor 7 (CCR7), cytotoxic T-lymphocyte-associated antigen (CTLA4), inducible T cell costimulatory (ICOS), and CD40 ligand (CD40LG) in urine.

Finally, as persistent PIS seems to be the link between the MetS and BPH and MetS patients have increased levels of CRP, several ILs and tumour necrosis factor (TNF)- α , also obese men with LUTS/BPH who have an increased insulin resistance, hypertension and hypercholesterolaemia may harbour persistent PIS [3, 7].

Several drug classes are approved and strongly recommended by the European Association of Urology (EAU) guidelines for the treatment of LUTS/BPH [2]. These include α_1 -adrenoceptor antagonists, 5 α -reductase inhibitors (5ARIs) and phosphodiesterase type 5 inhibitors (PDE5I). Moreover, although not approved for LUTS/BPH by health authorities, muscarinic receptor antagonists and beta-3 agonists are recommended by the EAU guidelines for men with moderate-to-severe LUTS who have mainly bladder storage symptoms [2]. The use of a particular drug class or the combination of different drug classes depends on, e.g., the type of LUTS, LUTS severity, PV, treatment duration, risk of progression and patient preference [2]. Although current data don't allow the EAU guidelines to make any recommendations about plant extracts for the treatment of BPH/LUTS, long-term clinical experience exists with plant extracts. The main plant extracts are *Cucurbita pepo* (pumpkin seeds), *Hypoxis rooperi* (South African star grass), *Pygeum africanum* (bark of the African plum tree), *Secale cereal* (rye pollen), *Serenoa repens* (syn. *Sabal serrulata*; saw palmetto) and *Urtica dioica* (roots of the stinging nettle) [2]. The most widely used [27, 28] and also most thoroughly studied plant extract in basic and clinical research for LUTS/BPH is *Serenoa repens* [28]. As the different extracts of the same plant available on the market do not necessarily have the same biological or clinical effects (e.g., due to the use of different extraction processes), the effects of one brand cannot be extrapolated to others [2, 29, 30]. A Cochrane meta-analysis published in 2012, including 5666 men (32 randomised controlled trials [RCTs] with trial lengths of 4–72 weeks), found no difference between *Serenoa repens* and placebo in changes in symptom scores [31]. However, this review combined data from various brands and the authors acknowledged that their findings may not be generalised to proprietary products [29]. Two more recent meta-analyses focussing on the hexanic extract of *Serenoa repens* (HESr) found that treatment with this extract reduced nocturia and improved maximum urinary flow rate (Q_{max}) compared to placebo and had similar efficacy to tamsulosin and short-term 5ARIs for relieving LUTS. The European Medicines Agency (EMA) has only granted HESr as a well-established medicinal

product since the use of this plant extract is supported by sufficient evidence of efficacy and safety [29, 32].

There is very limited data on the impact of α_1 -adrenoceptor antagonists and 5ARIs on persistent PIS. In a rat model of urine reflux-induced prostatic inflammation, silodosin prevented the upregulation of inflammation-associated proteins (IL-1 α , IL-1 β , IL-6, and TNF- α) and prostatic hypoxia, which was attributed to an improvement of prostate blood flow [33]. In a rat model of chronic bacterial prostatitis, finasteride statistically significantly decreased bacterial growth and reduced inflammatory cell infiltrations [34]. In a mouse xenograft model of human BPH, dutasteride reduced staining of cyclooxygenase-2 (Cox-2) and Ras homolog gene family, member A (RhoA) after already 2 months [5, 35]. In contrast, another study in a mouse model of BPH showed that finasteride increased persistent PIS (i.e., CD45 + cell foci) [36]. In a study of 17 patients with BPH undergoing transurethral resection of the prostate (TURP), doxazosin ($N=4$) reduced the staining of CD3 and CD68 compared to no treatment ($N=5$) [37]. Glutathion-S-transferase pi-1 (GSTP1: inactivates oxidant carcinogens) expression was only decreased in patients receiving both doxazosin and finasteride ($N=8$) suggesting that finasteride may interfere with the anti-inflammatory effect of doxazosin. A retrospective Korean study in 82 patients with BPH confirmed on biopsy and treated for 12 months with α_1 -adrenoceptor antagonists and 5ARIs showed reduced improvement in storage symptoms from 3 months onwards in those patients having high-grade chronic inflammation (based on the Irani grading system; $N=44$), whereas this did not occur in the low-grade group ($N=38$) [38]. Although this difference was not statistically significant, the patients in the high-grade group also more frequently needed surgery (9.1% of patients) because of AUR or insufficient therapeutic response compared to those in the low-grade group (0%). This suggests that LUTS/BPH patients harbouring persistent PIS may fail treatment with α_1 -adrenoceptor antagonists and 5ARIs in the long-term [5, 7, 8]. However, this study did not distinguish between the effect of α_1 -adrenoceptor antagonists and 5ARIs. Another retrospective Korean study in 111 LUTS/BPH patients treated with the α_1 -adrenoceptor antagonist tamsulosin 0.2 mg/day for only 3 months indicated that the improvement in LUTS was independent of the inflammation grade [39]. However, multivariate analysis suggested that longer duration of treatment was associated with decreased symptomatic improvement (odds ratio 0.92; 95% CI 0.85–0.99). This suggests that response to treatment with α_1 -adrenoceptor antagonists is influenced by the presence of persistent PIS but that at the same time it can modulate prostate immune cell activity [5]. The effect of both α_1 -adrenoceptor antagonists and 5ARIs on persistent PIS obviously needs further (clinical) investigation.

Regarding the PDE5I tadalafil, two animal studies have shown anti-inflammatory effects [40–42]. Moreover, in human BPH stromal cell lines, tadalafil blunted IL-8 secretion induced by metabolic stimuli or TNF- α [5, 40, 43]. In tissue of men with LUTS/BPH under low androgen conditions (i.e., treated with finasteride), tadalafil was able to reduce T-cell infiltration and related CCL5 secretion resulting in decreased proliferation of BPH epithelial cells [44].

Several in vitro and in vivo studies [45] have shown that HESr demonstrates inhibition of both inflammatory cells [46, 47] and a wide variety of inflammatory mediators and proteins [47–52], as well as deregulation of numerous genes playing a role in the proliferative, apoptotic, and inflammatory pathways of BPH itself [53]. In a double-blind, randomised study involving 206 LUTS/BPH patients treated with HESr (320 mg/day) or tamsulosin (0.4 mg/day) for 3 months, HESr reduced mean mRNA expression of the 15 out of 29 most frequently expressed inflammation-related genes in urine in 80% versus 33% of the genes with tamsulosin [54]. In addition, the macrophage migration inhibitory factor (MIF) was downregulated in a higher proportion of HESr (42.5%) as compared to tamsulosin-treated patients (23.9%) and upregulated in a lower proportion (43.8% versus 66.2%). Moreover, in contrast to tamsulosin, the reduction in mean total IPSS with HESr was larger in patients with

MIF overexpression at baseline (6.4 points) versus patients without MIF overexpression at baseline (4.5 points). In line with these anti-inflammatory effects, in a RCT of 97 patients with histologically/prostate biopsy confirmed prostatic inflammation, 6 months of treatment with HESr (320 mg/day) improved Irani's inflammation grading, aggressiveness, and total score in the biopsy to a statistically significant greater extent than in control patients who received no treatment (Fig. 2) [55]. Moreover, the inflammation score was upgraded in 25% of patients in the control group versus 6.1% of patients in the HESr group. Likewise, HESr also statistically significantly improved the immunohistological staining of antibodies against T and B-lymphocytes as well as macrophages. Therefore, in patients with LUTS/BPH, HESr may not only relieve LUTS to the same extent as α_1 -adrenoceptor antagonists and short-term 5ARIs, but also reduce the underlying inflammation [27, 28, 54–58]. This would be particularly useful in LUTS/BPH patients who have a high chance of harbouring persistent prostatic inflammation.

The effect of combination therapy of HESr with other approved LUTS/BPH treatments on LUTS has been investigated in several studies. In a French randomised study involving 352 LUTS/BPH patients treated for 1 year, the combination of tamsulosin (0.4 mg/day) and HESr (320 mg/





Fig. 2 Histopathological findings according to Irani's score at baseline (prostate biopsy 1) and after 6 months (prostate biopsy 2) [55]. The Irani score classifies prostatic inflammation on the basis of the extension of inflammatory cells and their effect on prostate tissue. A four-point scale is used for inflammation (0: no inflammatory cells, 1: scattered inflammatory cell infiltrate, 2: nonconfluent lymphoid

nodules, 3: large inflammatory areas with confluence of infiltrate) and aggressiveness (0: no contact between inflammatory cells and glandular epithelium, 1: contact between inflammatory cell infiltrate and glandular epithelium, 2: clear but limited, i.e., <25% of the examined material, shows glandular epithelium disruption, 3: glandular epithelium disruption in >25% of the examined material)

Fig. 3 Improvement in mean IPSS after ≥ 12 months of treatment with silodosin 8 mg/day (SIL) or its combination with HESr 320 mg/day (SIL + HESr) in 186 men with LUTS/BPH [61]



day) was not significantly superior to tamsulosin alone with regard to improvement of the total IPSS (6.0 versus 5.2 points, respectively; $P=0.286$) [59]. Nevertheless, an open-label, randomised, Korean study in 103 LUTS/BPH patients showed that 1 year of treatment with the combination of tamsulosin (0.2 mg/day) and HESr (320 mg/day) was equally effective as tamsulosin monotherapy in reducing total and voiding IPSS, but resulted in a greater improvement of the storage IPSS (1.9 versus 0.9 points, $P=0.021$) [59, 60]. In both studies, there was only a limited increase in adverse drug reactions in the combination group [59, 60], mainly gastrointestinal disorders [60]. A third Italian cross-sectional, matched-pair study compared monotherapy of silodosin (8 mg/day) to its combination with HESr in 186 LUTS/BPH patients treated for ≥ 1 year [61]. The mean improvement in total IPSS was significantly greater in patients receiving combination therapy (6.43 points) compared to those receiving silodosin alone (3.21 points, $P=0.002$); of clinical relevance, this applied for both the voiding and storage component of the IPSS (Fig. 3). The greater improvement in Q_{max} with combination therapy (4.3 versus 2.3 mL/s) was not significant ($P=0.15$). Currently, no studies are published comparing the efficacy of the combination of an 5ARI or PDE5I with HESr versus monotherapy.

Conclusions

This extensive, non-systematic literature review indicates that persistent PIS is particularly evident in men with LUTS/BPH who are older, have a large PV, more severe

(storage) LUTS and/or MetS. Persistent PIS per se contributes to the development of BPH and also increases the risk of (faster) progression. Of the medical therapies approved for the treatment of LUTS/BPH, HESr showed the greatest evidence for a reduction of persistent PIS. However, it should be noted that there is limited data on the effect of LUTS/BPH medical therapies on persistent PIS and these studies are often limited by their low level of evidence. HESr seems to relieve LUTS to the same extent as α_1 -adrenoceptor antagonists and short-term 5ARIs and to reduce the underlying inflammation. Combining HESr with an α_1 -adrenoceptor antagonist may relieve storage symptoms (who are linked to persistent PIS) but also voiding symptoms to a greater extent than α_1 -adrenoceptor antagonist monotherapy. Future well-designed clinical trials, with a good level of evidence, should (better) evaluate the impact of HESr, PDE5I, α_1 -adrenoceptor antagonists and 5ARIs (alone or in combination) on persistent PIS and the potential impact of targeting the inflammatory pathway on LUTS/BPH development and progression.

Acknowledgements The authors are grateful to Ismar Healthcare NV who provided literature research and medical writing assistance; this was supported by an educational grant by Pierre Fabre Pharma Italy.

Author contributions CN: critical review and editing of the manuscript. VF: critical review and editing of the manuscript. MG: critical review and editing of the manuscript. AS: critical review and editing of the manuscript.

Funding This work was supported by an educational grant by Pierre Fabre Pharma Italy.

Compliance with ethical standards

Conflict of interest C De Nunzio: consultant for Pierre-Fabre, Jansen and Astellas. V Ficarra: honoraria for speaking at symposia from Pierre Fabre and research grants from IDIPharma. M Gacci: company consultant, trial participation, fellowship, travel grant, receipt of grants/research supports for Astellas, Bayer, GSK, Ibsa, Konpharma, Lilly, Menarini, Pierre Fabre and Recordati. A Salonia: no conflict of interest.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

References

- Berry SJ, Coffey DS, Walsh PC, Ewing LJ (1984) The development of human benign prostatic hyperplasia with age. *J Urol* 132:474–479. <https://doi.org/10.1016/S0022-5347%2817%2949698-4>
- Gravas S, Cornu JN, Gacci M, Gratzke C, Herrmann TRW, Mamoulakis C, Rieken M, Speakman MJ, Tikkinen KAO (2019) Management of non-neurogenic male LUTS. EAU guidelines 2019. <https://uroweb.org/guideline/treatment-of-non-neurogenic-male-luts/#1>. Accessed Aug 2019
- He Q, Wang Z, Liu G, Daneshgari F, MacLennan GT, Gupta S (2016) Metabolic syndrome, inflammation and lower urinary tract symptoms: possible translational links. *Prostate Cancer Prostatic Dis* 19:7–13. <https://doi.org/10.1038/pcan.2015.43>
- De Nunzio C, Kramer G, Marberger M, Montironi R, Nelson W, Schröder F, Sciarra A, Tubaro A (2011) The controversial relationship between benign prostatic hyperplasia and prostate cancer: the role of inflammation. *Eur Urol* 60:106–117. <https://doi.org/10.1016/j.eururo.2011.03.055>
- De Nunzio C, Presicce F, Tubaro A (2016) Inflammatory mediators in the development and progression of benign prostatic hyperplasia. *Nat Rev Urol* 13:613–626. <https://doi.org/10.1038/nrurol.2016.168>
- Bostanci Y, Kazzazi A, Momtahan S, Laze J, Djavan B (2013) Correlation between benign prostatic hyperplasia and inflammation. *Curr Opin Urol* 23:5–10. <https://doi.org/10.1097/MOU.0b013e32835abd4a>
- Gandaglia G, Briganti A, Gontero P, Mondaini N, Novara G, Salonia A, Sciarra A, Montorsi F (2013) The role of chronic prostatic inflammation in the pathogenesis and progression of benign prostatic hyperplasia (BPH). *BJU Int* 112:432–441. <https://doi.org/10.1111/bju.12118>
- Ficarra V, Rossanese M, Zazzara M, Giannarini G, Abbinante M, Bartoletti R, Mirone V, Scaglione F (2014) The role of inflammation in lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) and its potential impact on medical therapy. *Curr Urol Rep* 15:463. <https://doi.org/10.1007/s11934-014-0463-9>
- Irani J, Levillain P, Goujon JM, Bon D, Dore B, Aubert J (1997) Inflammation in benign prostatic hyperplasia: correlation with prostate specific antigen value. *J Urol* 157:1301–1303. <https://doi.org/10.1016/S0022-5347%2801%2964957-7>
- Di Silverio F, Gentile V, De Matteis A, Mariotti G, Giuseppe V, Luigi PA, Sciarra A (2003) Distribution of inflammation, pre-malignant lesions, incidental carcinoma in histologically confirmed benign prostatic hyperplasia: a retrospective analysis. *Eur Urol* 43:164–175. [https://doi.org/10.1016/S0302-2838\(02\)00548-1](https://doi.org/10.1016/S0302-2838(02)00548-1)
- Roehrborn C et al (2005) The impact of acute and chronic inflammation in baseline biopsy on the risk of clinical progression of BPH: results from the MTOPS study. *J Urol* 173(Suppl):346 (abstract 1277)
- Nickel JC, Roehrborn CG, O'Leary MP, Bostwick DG, Somerville MC, Rittmaster RS (2008) The relationship between prostate inflammation and lower urinary tract symptoms: examination of baseline data from the REDUCE trial. *Eur Urol* 54:1379–1384. <https://doi.org/10.1016/j.eururo.2007.11.026>
- Zlotta AR, Egawa S, Pushkar D, Govorov A, Kimura T, Kido M, Takahashi H, Kuk C, Kovylyna M, Aldaoud N, Fleshner N, Finelli A, Klotz L, Lockwood G, Sykes J, van der Kwast T (2014) Prevalence of inflammation and benign prostatic hyperplasia on autopsy in Asian and Caucasian men. *Eur Urol* 66:619–622. <https://doi.org/10.1016/j.eururo.2014.06.026>
- Robert G, Descazeaud A, Allory Y, Vacherot F, de la Taille A (2009) Should we investigate prostatic inflammation for the management of benign prostatic hyperplasia? *Eur Urol Suppl* 8:879–886. <https://doi.org/10.1016/j.eursup.2009.11.004>
- Robert G, Descazeaud A, Nicolaiew N, Terry S, Sirab N, Vacherot F, Maillé P, Allory Y, de la Taille A (2009) Inflammation in benign prostatic hyperplasia: a 282 patients' immunohistochemical analysis. *Prostate* 69:1774–1780. <https://doi.org/10.1002/pros.21027>
- Kim SH, Jung KI, Koh JS, Min KO, Cho SY, Kim HW (2013) Lower urinary tract symptoms in benign prostatic hyperplasia patients: orchestrated by chronic prostatic inflammation and prostatic calculi? *Urol Int* 90:144–149. <https://doi.org/10.1159/000342643>
- Nickel JC, Roehrborn CG, Castro-Santamaria R, Freedland SJ, Moreira DM (2016) Chronic prostate inflammation is associated with severity and progression of benign prostatic hyperplasia, lower urinary tract symptoms and risk of acute urinary retention. *J Urol* 196:1493–1498. <https://doi.org/10.1016/j.juro.2016.06.090>
- Tuncel A, Uzun B, Eruyar T, Karabulut E, Seckin S, Atan A (2005) Do prostatic infarction, prostatic inflammation and prostate morphology play a role in acute urinary retention? *Eur Urol* 48:277–284. <https://doi.org/10.1016/j.eururo.2005.05.001>
- Mishra VC, Allen DJ, Nicolaou C, Sharif H, Hudd C, Karim OM, Motiwala HG, Laniado ME (2007) Does intraprostatic inflammation have a role in the pathogenesis and progression of benign prostatic hyperplasia? *BJU Int* 100:327–331. <https://doi.org/10.1111/j.1464-410X.2007.06910.x>
- van Vuuren SPJ, Heyns CF, Zarrabi AD (2012) Significance of histological prostatitis in patients with urinary retention and underlying benign prostatic hyperplasia or adenocarcinoma of the prostate. *BJU Int* 109:1194–1197. <https://doi.org/10.1111/j.1464-410X.2011.10527.x>
- Nickel JC, Roehrborn CG, O'Leary MP, Bostwick DG, Somerville MC, Rittmaster RS (2007) Examination of the relationship between symptoms of prostatitis and histological inflammation: baseline data from the REDUCE chemoprevention trial. *J Urol* 178(3(Pt 1)):896–901. <https://doi.org/10.1016/j.juro.2007.05.041>

22. Ficarra V (2013) Is chronic prostatic inflammation a new target in the medical therapy of lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH)? *BJU Int* 12:421–422. <https://doi.org/10.1111/bju.12177>
23. Bardan R, Dumache R, Dema A, Cumpănas A, Bucuras V (2014) The role of prostatic inflammation biomarkers in the diagnosis of prostate diseases. *Clin Biochem* 47(10–11):909–915. <https://doi.org/10.1016/j.clinbiochem.2014.02.008>
24. Penna G, Mondaini N, Amuchastegui S, Degli Innocenti S, Carini M, Giubilei G, Fibbi B, Colli E, Maggi M, Adorini L (2007) Seminal plasma cytokines and chemokines in prostate inflammation: interleukin 8 as a predictive biomarker in chronic prostatitis/chronic pelvic pain syndrome and benign prostatic hyperplasia. *Eur Urol* 51:524–533. <https://doi.org/10.1016/j.eururo.2006.07.016>
25. Lotti F, Maggi M (2013) Interleukin 8 and the male genital tract. *J Reprod Immunol* 100:54–65. <https://doi.org/10.1016/j.jri.2013.02.004>
26. Liu L, Li Q, Han P, Li X, Zeng H, Zhu Y, Wei Q (2009) Evaluation of interleukin-8 in expressed prostatic secretion as a reliable biomarker of inflammation in benign prostatic hyperplasia. *Urology* 74:340–344. <https://doi.org/10.1016/j.urology.2009.02.064>
27. Novara G, Giannarini G, Alcaraz A, C  zar-Olmo JM, Descalzeau A, Montorsi F, Ficarra V (2016) Efficacy and safety of hexanic lipidosterolic extract of *Serenoa repens* (Permixon) in the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia: systematic review and meta-analysis of randomized controlled trials. *Eur Urol Focus* 2:553–561. <https://doi.org/10.1016/j.euf.2016.04.002>
28. Vela-Navarrete R, Alcaraz A, Rodr  guez-Antol  n A, Mi  ana L  pez B, Fern  ndez-G  mez JM, Angulo JC, Castro D  az D, Romero-Otero J, Brenes FJ, Carballido J, Molero Garc  a JM, Fern  ndez-Pro Ledesma A, C  zar Olmos JM, Manasanch Dalmau J, Subirana Cachinero I, Herdman M, Ficarra V (2018) Efficacy and safety of a hexanic extract of *Serenoa repens* (Permixon^{  }) for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH): systematic review and meta-analysis of randomised controlled trials and observational studies. *BJU Int* 122:1049–1065. <https://doi.org/10.1111/bju.14362>
29. Scaglione F (2015) How to choose the right *Serenoa repens* extract. *Eur Urol Suppl* 14:e1464–e1469. [https://doi.org/10.1016/S1569-9056\(15\)30501-7](https://doi.org/10.1016/S1569-9056(15)30501-7)
30. Marti G, Joulia P, Amiel A, Fabre B, David B, Fabre N, Fiorini-Puybaret C (2019) Comparison of the phytochemical composition of serenoa repens extracts by a multiplexed metabolomic approach. *Molecules* 24(12):2208. <https://doi.org/10.3390/molecules24122208>
31. Tacklind J, Macdonald R, Rutks I, Stanke JU, Wilt TJ (2012) *Serenoa repens* for benign prostatic hyperplasia. *Cochrane Database Syst Rev* 12:CD001423. <https://doi.org/10.1002/14651858.CD001423.pub3>
32. European Medicines Agency (2015) Assessment report on *Serenoa repens* (W. Bartram) Small, fructus. Final, 24 November 2015. <https://www.ema.europa.eu/en/medicines/herbal/sabalisserrulatae-fructus>. Accessed Aug 2019.
33. Funahashi Y, Majima T, Matsukawa Y, Yamamoto T, Yoshida M, Gotoh M (2017) Intraprostatic reflux of urine induces inflammation in a rat. *Prostate* 77:164–172. <https://doi.org/10.1002/pros.23257>
34. Seo SI, Lee SJ, Kim JC, Choi YJ, Kim SW, Hwang TK, Cho YH (2003) Effects of androgen deprivation on chronic bacterial prostatitis in a rat model. *Int J Urol* 10:485–491. <https://doi.org/10.1046/j.1442-2042.2003.00666.x>
35. Tsujimura A, Fukuhara S, Soda T, Takezawa K, Kiuchi H, Takao T, Miyagawa Y, Nonomura N, Adachi S, Tokita Y, Nomura T (2015) Histologic evaluation of human benign prostatic hyperplasia treated by dutasteride: a study by xenograft model with improved severe combined immunodeficient mice. *Urology* 85:e271–e278. <https://doi.org/10.1016/j.urology.2014.09.024>
36. Pigat N, Reyes-Gomez E, Boutillon F, Palea S, Barry Delongchamps N, Koch E, Goffin V (2019) Combined sabal and urtica extracts (WS^{  } 1541) exert anti-proliferative and anti-inflammatory effects in a mouse model of benign prostate hyperplasia. *Front Pharmacol* 10:311. <https://doi.org/10.3389/fphar.2019.00311>
37. Park DS, Shim JY (2008) Histologic influence of doxazosin and finasteride in benign prostatic hyperplasia accompanying chronic inflammation. *Urol Int* 81:441–446. <https://doi.org/10.1159/000167844>
38. Kwon YK, Choe MS, Seo KW, Park CH, Chang HS, Kim BH, Kim CI (2010) The effect of intraprostatic chronic inflammation on benign prostatic hyperplasia treatment. *Korean J Urol* 51:266–270. <https://doi.org/10.4111/kju.2010.51.4.266>
39. Lee HN, Kim TH, Lee SJ, Cho WY, Shim BS (2014) Effects of prostatic inflammation on LUTS and alpha blocker treatment outcomes. *Int Braz J Urol* 40:356–366. <https://doi.org/10.1590/S1677-5538.IBJU.2014.03.09>
40. Gacci M, Andersson KE, Chapple C, Maggi M, Mirone V, Oelke M, Porst H, Roehrborn C, Stief C, Giuliano F (2016) Latest evidence on the use of phosphodiesterase type 5 inhibitors for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. *Eur Urol* 70:124–133. <https://doi.org/10.1016/j.eururo.2015.12.048>
41. Morelli A, Comeglio P, Filippi S, Sarchielli E, Vignozzi L, Maneschi E, Cellai I, Gacci M, Lenzi A, Vannelli GB, Maggi M (2013) Mechanism of action of phosphodiesterase type 5 inhibition in metabolic syndrome-associated prostate alterations: an experimental study in the rabbit. *Prostate* 73:428–441. <https://doi.org/10.1002/pros.22584>
42. Okamoto K, Kurita M, Yamaguchi H, Numakura Y, Oka M (2017) Effect of tadalafil on chronic pelvic pain and prostatic inflammation in a rat model of experimental autoimmune prostatitis. *Prostate* 78:707–713. <https://doi.org/10.1002/pros.23514>
43. Vignozzi L, Gacci M, Cellai I, Morelli A, Maneschi E, Comeglio P, Santi R, Filippi S, Sebastianelli A, Nesi G, Serni S, Carini M, Maggi M (2013) PDE5 inhibitors blunt inflammation in human BPH: a potential mechanism of action for PDE5 inhibitors in LUTS. *Prostate* 73:1391–1402. <https://doi.org/10.1002/pros.22686>
44. Jin S, Xiang P, Liu J, Yang Y, Hu S, Sheng J, He Q, Yu W, Han W, Jin J, Peng J (2019) Activation of cGMP/PKG/p65 signaling associated with PDE5-Is downregulates CCL5 secretion by CD8⁺ T cells in benign prostatic hyperplasia. *Prostate* 79:909–919. <https://doi.org/10.1002/pros.23801>
45. Robert GY (2015) Comparison of the effects of the hexanic extract of *Serenoa repens* (Permixon) and tamsulosin on inflammatory biomarkers in the treatment of benign prostatic hyperplasia-related lower urinary tract symptoms. *Eur Urol Suppl* 14:e1470–e1474
46. Vela Navarrete R, Garcia Cardoso JV, Barat A, Manzarbeitia F, L  pez Farr   A (2003) BPH and inflammation: pharmacological effects of permixon on histological and molecular inflammatory markers. Results of a double blind pilot clinical assay. *Eur Urol* 44:549–555. [https://doi.org/10.1016/s0302-2838\(03\)00368-3](https://doi.org/10.1016/s0302-2838(03)00368-3)
47. Bernichtein S, Pigat N, Camparo P, Latil A, Viltard M, Friedlander G, Goffin V (2015) Anti-inflammatory properties of Lipidosterolic extract of *Serenoa repens* (Permixon^{  }) in a mouse model of prostate hyperplasia. *Prostate* 75:706–722. <https://doi.org/10.1002/pros.22953>
48. Paubert-Braquet M, Mencia Huerta JM, Cousse H, Braquet P (1997) Effect of the lipidic lipidosterolic extract of *Serenoa repens* (Permixon^{  }) on the ionophore A23187-stimulated production of leukotriene B4 (LTB4) from human polymorphonuclear

- neutrophils. Prostaglandins Leukot Essent Fatty Acids 57:299–304. [https://doi.org/10.1016/S0952-3278\(97\)90548-2](https://doi.org/10.1016/S0952-3278(97)90548-2)
49. Bonvissuto G, Minutoli L, Morgia G, Bitto A, Polito F, Irrera N, Marini H, Squadrito F, Altavilla D (2011) Effect of *Serenoa repens*, lycopene, and selenium on proinflammatory phenotype activation: an in vitro and in vivo comparison study. Urology 77:e216–e249. <https://doi.org/10.1016/j.urology.2010.07.514>
 50. Latil A, Libon C, Templier M, Junquero D, Lantoine-Adam F, Nguyen T (2012) Hexanic lipidosterolic extract of *Serenoa repens* inhibits the expression of two key inflammatory mediators, MCP-1/CCL2 and VCAM-1, in vitro. BJU Int 110(6 Pt B):E301–E307. <https://doi.org/10.1111/j.1464-410X.2012.11144.x>
 51. Colado-Velázquez J III, Mailloux-Salinas P, Medina-Contreras JML, Cruz-Robles D, Bravo G (2015) Effect of *Serenoa repens* on oxidative stress, inflammatory and growth factors in obese wistar rats with benign prostatic hyperplasia. Phytother Res 29:1525–1531. <https://doi.org/10.1002/ptr.5406>
 52. Chiavaroli A, Recinella L, Ferrante C, Locatelli M, Carradori S, Macchione N, Zengin G, Leporini L, Leone S, Martinotti S, Brunetti L, Vacca M, Menghini L, Orlando G (2017) *Crocus sativus*, *Serenoa repens* and *Pinus massoniana* extracts modulate inflammatory response in isolated rat prostate challenged with LPS. J Biol Regul Homeost Agents 31:531–541
 53. Sirab N, Robert G, Fasolo V, Descazeaud A, Vacherot F, de la Taille A, Terry S (2013) Lipidosterolic extract of *Serenoa repens* modulates the expression of inflammation related-genes in benign prostatic hyperplasia epithelial and stromal cells. Int J Mol Sci 14:14301–14320. <https://doi.org/10.3390/ijms140714301>
 54. Latil A, Pétrissans MT, Rouquet J, Robert G, de la Taille A (2015) Effects of hexanic extract of *Serenoa repens* (Permixon® 160 mg) on inflammation biomarkers in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia. Prostate 75:1857–1867. <https://doi.org/10.1002/pros.23059>
 55. Gravas S, Samarinas M, Zacharouli K, Karatzas A, Tzortzis V, Koukoulis G, Melekos M (2019) The effect of hexanic extract of *Serenoa repens* on prostatic inflammation: results from a randomized biopsy study. World J Urol 37:539–544. <https://doi.org/10.1007/s00345-018-2409-1>
 56. Alcaraz A, Carballido-Rodríguez J, Unda-Urzaiz M, Medina-López R, Ruiz-Cerdá JL, Rodríguez-Rubio F, García-Rojo D, Brenes-Bermúdez FJ, Cózar-Olmo JM, Baena-González V, Manasanch J (2016) Quality of life in patients with lower urinary tract symptoms associated with BPH: change over time in real-life practice according to treatment—the QUALIPROST study. Int Urol Nephrol 48:645–656. <https://doi.org/10.1007/s11255-015-1206-7>
 57. Carraro JC, Raynaud JP, Koch G, Chisholm GD, Di Silverio F, Teillac P, Calais Da Silva F, Cauquil J, Chopin DK, Hamdy FC, Hanus M, Hauri D, Kalinteris A, Marencak J, Perier A, Perrin P (1996) Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia: a randomized international study of 1098 patients. Prostate 29:231–240. [https://doi.org/10.1002/\(SICI\)1097-0045\(199610\)29:4%3c231:AID-PROS4%3e3.0.CO;2-E](https://doi.org/10.1002/(SICI)1097-0045(199610)29:4%3c231:AID-PROS4%3e3.0.CO;2-E)
 58. Debruyne F, Koch G, Boyle P, Da Silva FC, Gillenwater JG, Hamdy FC, Perrin P, Teillac P, Vela-Navarrete R, Raynaud JP (2002) Comparison of a phytotherapeutic agent (Permixon) with an alpha-blocker (Tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international study. Eur Urol 41:497–507
 59. Glemain P, Coulange C, Billebaud T, Gattegno B, Muszynski R, Loeb G (2002) Tamsulosine avec ou sans *Serenoa repens* dans l’hypertrophie bénigne de la prostate: l’essai OCOS [Tamsulosin with or without *Serenoa repens* in benign prostatic hyperplasia: the OCOS trial]. Prog Urol 12:395–403
 60. Ryu YW, Lim SW, Kim JH, Ahn SH, Choi JD (2015) Comparison of tamsulosin plus serenoa repens with tamsulosin in the treatment of benign prostatic hyperplasia in Korean men: 1-year randomized open label study. Urol Int 94:187–193. <https://doi.org/10.1159/000366521>
 61. Boeri L, Capogrosso P, Ventimiglia E, Cazzaniga W, Pederzoli F, Moretti D, Dehò F, Montanari E, Montorsi F, Salonia A (2017) Clinically meaningful improvements in LUTS/BPH severity in men treated with silodosin plus hexanic extract of *Serenoa repens* or silodosin alone. Sci Rep 7:15179. <https://doi.org/10.1038/s41598-017-15435-0>

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.